Valvular heart disease in cancer patients - prevalence, relevance, and therapeutic management - preliminary results from the CESAR study

11 December 2025 (08:00 - 15:30)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Maximilian Autherith

Medical University of Vienna, Vienna (Austria)

5 More presentations in this session

Presentation thumbnail

Comprehensive echocardiographic assessment of the diastolic cardiac function in children treated for acute lymphoblastic leukemia, preliminary results.

Doctor J. Haponiuk-Skwarlinska (Warsaw, PL)

Abstract Slides

Presentation thumbnail

The utility of serial global longitudinal strain and biomarkers in identifying subclinical cardiotoxicity in cancer patients receiving anthracycline or trastuzumab therapy

Doctor N. Shaaban (Alexandria, EG)

Abstract Slides

Presentation thumbnail

Dynamic cardiac toxicity monitoring in hematological tumor patients based on time thresholds and chemotherapy stratification

Doctor M. Zhang (Hangzhou, CN)

Abstract Slides

Presentation thumbnail

Echocardiographic and biochemical evidences of cardioprotection by dapagliflozin in non-diabetic models exposed to sequential anthracyclines and trastuzumab therapy

Doctor N. Maurea (Naples, IT)

Abstract Slides

Presentation thumbnail

Thick but safe: revisiting the role of epicardial adipose tissue in chemotherapy-induced cardiac dysfunction

Assistant Professor H. Kim (Cheonan-si, KR)

Abstract Slides

Access the full session

Session thumbnail

Role of echocardiography on cardio-oncology

The Event

Event poster

EACVI 2025

11 December - 13 December 2025

You may be interested in

Congress Presentation

Valvular heart disease

Congress Presentation

When to use cardiac magnetic resonance in aortic stenosis

Congress Presentation

Assessment of aortic BVD: step-by-step approach

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources